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Background. Cardiovascular events represent a major source of morbidity and mortality after liver transplantation and will likely increase given the aging population and nonalcoholic fatty liver disease as a leading indication for transplant. The optimal cardiovascular risk stratification approach in this evolving patient population remains unclear. The aims of this systematic review are to: (1) refine the definition, (2) characterize the incidence, and (3) identify risk factors for cardiovascular events post-liver transplantation. Additionally, we evaluated performance characteristics of different cardiac testing modalities. Methods. MEDLINE via PubMed, EMBASE, Web of Science, and Scopus were searched for studies published between 2002 and 2016 (model of end-stage liver disease era). Two authors independently reviewed articles to select eligible studies and performed data abstraction. Results. Twentynine studies representing 57 493 patients from 26 unique cohorts were included. Definitions of cardiovascular outcomes were highly inconsistent. Incidence rates were widely variable: 1% to 41% for outcomes of 6 months or shorter and 0% to 31% for outcomes longer than 6 months. Multivariate analyses demonstrated that older age and history of cardiac disease were the most consistent predictors of cardiovascular events posttransplant (significant in 8/23 and 7/22, studies, respectively). Predictive capacity of various cardiac imaging modalities was also discrepant. Conclusions. The true incidence of cardiovascular outcomes post-liver transplant remains unknown in large part due to lack of consensus regarding outcome definition. Overall, poor data quality and gaps in knowledge limit the ability to clearly identify predictors of outcomes, but existing data support a more aggressive risk stratification protocol for patients of advanced age and/or with preexisting cardiac disease. A dverse cardiovascular (CV) events represent a major cause of morbidity and mortality after liver transplantation (LT). 1, 2 The clinical profile of LT candidates is evolving, and it is anticipated that the incidence of adverse CV events is likely to continue to increase in this setting. The differences include an overall aging patient population, nonalcoholic fatty liver disease (NAFLD) becoming a leading indication for LT, higher burden of chronic kidney disease going into transplant, and increasing utilization of dual liver-kidney transplantation. 3, 4 Although there are existing guidelines from hepatology, transplant surgery, and cardiology professional societies regarding CV risk stratification before LT, it remains unclear if the performance characteristics of these approaches remain satisfactory in this evolving patient population. [5] [6] [7] Specifically, it would be of interest to identify subgroups of LT candidates who are at highest risk for adverse CVoutcomes post-LT such that a CV risk stratification approach could then be tailored appropriately. This approach would help balance the risks, benefits, and costs of varying cardiac testing modalities and ideally also optimize posttransplant outcomes.
Multiple studies have evaluated risk factors for CV events post-LT and varying approaches to cardiac risk stratification in LT candidates. Data from these studies have been conflicting however with varying incidence rates reported for CV outcomes post-LT and differing risk factors identified as being associated with CVevents post-LT. In addition, the performance characteristics of different modalities of cardiac testing in LT candidates have also been contradictory. In general, dobutamine stress echocardiography (DSE) remains a mainstay of first line cardiac testing in LT candidates, though the accuracy of this tool in appropriately identifying high risk patients is in doubt. 8, 9 To date, there has not been a systematic summary of the existing literature on this topic. As such, it has been difficult for clinicians to understand the true scope of the burden of CVevents post-LT, to identify which patients are at highest risk for these outcomes, and to then apply a high yield cardiac risk stratification approach to their individual patients. Therefore, we performed a systematic review of the literature to: (1) refine the definition, (2) characterize the incidence, and (3) identify risk factors for CV events post-LT. Secondary aims of this study were to assess existing predictive models for risk of CV events post-LT, and to evaluate performance characteristics of different modalities of cardiac testing in LT candidates.
MATERIALS AND METHODS

Data Sources and Search Strategy
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations in conducting this systematic review. 10 With the assistance of a medical research librarian, we performed serial literature searches for articles of interest. MEDLINE (via PubMed), EMBASE, Web of Science and Scopus were searched using the following keywords: "liver transplantation," "cardiovascular diseases," or "cardiac imaging," or "cardiac imaging techniques." Boolean operators and medical subject heading terms as well as other controlled vocabulary were used to enhance electronic searches. An example of specific search strategy details is shown in Table S1 , SDC, http://links.lww.com/TP/B419.
All human subject studies published in full-text or abstract were eligible for inclusion. Additional studies of interest were identified by hand searches of bibliographies, cited reference tracking, and consultation with clinical experts on the topic. The search time frame was selected to begin in 2002 because this represents the initiation of the model of endstage liver disease (MELD) era. The initial search was performed in December 2015, and the search was last updated on December 1, 2016.
Study Eligibility and Selection Criteria
Two study authors sequentially determined study eligibility. Studies were initially screened by the first author; decisions about study inclusion were made independently by 2 authors (M.A.K. and P.S. or D.F.). Differences in opinion regarding study inclusion were resolved through consensus. Adult (≥18 years) human subject studies that systematically evaluated either (1) risk factors or predictors of CV events after LT; or (2) performance characteristics of different modalities of cardiac imaging in LT candidates to risk stratify for CV events post-LT were included.
We excluded studies that: (1) only enrolled patients with Living Donor LT (due to the fact that deceased donor transplants represent the majority of LT presently and risks for and rates of CV events post-LT in patients undergoing living donor LT may differ from those receiving deceased donor LT), (2) only evaluated specific subgroups of patients (ie, hepatitis C virus [HCV] alone), (3) only evaluated risk of overall mortality, (4) only evaluated risk of developing 1 specific cardiac outcome unless this 1 outcome was either myocardial infarction or cardiac death, (5) evaluated only 1 predictor (ie, effect of immunosuppressive agent), or (6) evaluated only intraoperative risk factors for CV events. These studies were excluded because we were interested in preoperative risk assessment for the comprehensive range of clinically relevant adverse CV events among the broader cohort of patients in need of LT. Lastly, studies for which no translation into English language was available were also excluded.
Data Abstraction and Validity Assessment
Data from eligible studies were abstracted by 2 authors using a standardized template adapted from the Cochrane Collaboration. 11 For all studies, we recorded: study design, sample size, patient population characteristics, duration of follow-up, predictor variables studied, outcomes measured, criteria used to define these outcomes, incidence of outcomes, and measures of association/prediction of risk for these outcomes. For cardiac imaging studies, we additionally evaluated performance characteristics of these techniques including sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) for assessing risk of cardiac outcomes post-LT. We accepted the outcome definitions as stated by each study without independently validating or reviewing their data. Study authors were directly contacted for additional, unpublished data when necessary.
Assessment of Risk of Bias and Study Quality
Each study was assessed for risk of study bias and study quality. Given that all the included studies were nonrandomized cohort studies, the Newcastle-Ottawa Scale was used to judge study quality as recommended by the Cochrane Collaboration. 12 This scale uses a star system to assess the quality of a study based on 3 domains: selection of the study population, comparability of the study groups, and method of outcomes assessment. For our review, we excluded comparability components of the scale as the included studies lacked comparison groups. Studies which received stars in every domain were assessed as being of high quality.
Data Synthesis and Analysis
Given the substantial variation in definition of outcomes and inclusion/exclusion criteria, meta-analysis was not able to be performed. Two authors qualitatively synthesized the results of the included studies. Studies were categorized according to the outcome of interest (predictors of CV events or cardiac imaging performance characteristics for risk stratification), and the study time interval [short-term CV events only (≤6 months) vs those that also assessed longer-term CV events (>6 months)].
RESULTS
Studies Included in the Systematic Review
One thousand nine hundred seventy-six unique articles were identified by our systematic literature search (Figure 1 ). On the basis of abstract review, 76 were selected for full-text review. Two study authors classified 29 articles as meeting the predefined criteria for analysis. In total, these 29 studies included 57 493 unique patients from 27 separate patient cohorts. 2, 8, 9, Twenty-three of these studies investigated predictors of CV events post-LT and 6 focused primarily on cardiac imaging performance characteristics for risk stratification. We contacted 2 authors to obtain additional unpublished data.
Characteristics of Studies on Overall Risk Factors for CV Events Post-LT
All 23 studies were retrospective analyses. The sample size for included studies varied tremendously (range, 76 to 54 697 patients), though the majority had between 100 and 500 patients (n = 17). Five studies had overlapping cohorts. 21, 22, 32, 34, 35 One study consisted of data collected in the OPTN database. 32 These studies were included in the review despite overlapping cohorts given differences in predictors examined and outcomes evaluated. Among studies that evaluated risk for CV events at 6 months or less, the average duration of follow-up was 2.8 months (range, 1-6 months). For studies including outcomes occurring longer than 6 months post-LT, the average duration of follow-up was 5.6 years (range, 1-10 years).
The studies had varied inclusion and exclusion criteria as detailed in Table 1 . Thirteen studies excluded patients with prior LTs and 7 excluded patients undergoing multiorgan transplant. The age of included patients was reported as both age at initial LT evaluation and age at time of LT. The average age reported was 53 years (range, 42.3-57). The studies tended to have a male predominance (average, 64.6%; range, 45.6%-79%). MELD score was reported as both MELD at the time of LT and at the time of initial LT evaluation. The average MELD reported across studies was 18.2 (range, 13.4-22). The indication for LT was most often categorized as viral hepatitis (32.8%; range, 6%-71%) with varying frequencies of alcoholic liver disease (average, 17.6%; range, 8%-40%). Notably, NAFLD/nonalcoholic steatohepatitis (NASH) or cryptogenic cirrhosis was an uncommon indication for LT in the majority of these studies (average, 8.8%; range, 2-19%). The average body mass index (BMI) was in the overweight and not obese category (27.1; range, 23.9-29). The prevalence of comorbid diabetes was 21.4% (range, 10%-41%).
Characteristics of Studies of Cardiac Imaging Modalities
A total of 6 studies had a primary aim of evaluating different modalities of cardiac imaging for risk stratification of LT candidates. All were retrospective analyses. Sample size was comparatively much smaller and ranged from 24 to 339, with the majority consisting of less than 100 patients (N = 4). The average duration of follow-up was 2.9 years (range, 9 months to 7 years). The imaging modalities assessed in these studies included DSE, coronary computed tomography angiography, and Single Photon Emission Computed Tomography (SPECT). The individual inclusion and exclusion criteria are detailed in Table 2 . The average age was 53 years (range, 42.7-56). These studies had a more notable male predominance (average, 71.5%; range, 63%-78%) compared with the clinical prediction studies. The average MELD reported (captured as MELD at time of LT evaluation) was 14.8 (range, 11.8-16.5). The indication for LT was also predominantly either viral [31.1%; range, 17.9-54) or alcoholic liver disease (22.5%; range, 11-31). The average BMI was only reported in 2 of the 6 studies. The prevalence of co-morbid diabetes was 25.4% (range, 16%-45%).
Definition of CV Events
In all studies, outcomes were identified by retrospective chart review. Methods to confirm outcomes varied from sole use of ICD-9 coding to manual chart review. Definitions for individual cardiac events varied dramatically (Tables 3 and  4) . Four studies did not provide any details regarding the definition of CV outcomes. 17, 29, 30, 36 The majority of studies examined a composite outcome including coronary artery disease with an episode of myocardial ischemia, heart failure, and arrhythmias (N = 20). Three studies only evaluated CV-related mortality.
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Incidence of CV Events
The incidence rates for CV events post-LT for each study are detailed in Tables 3 and 4 . The incidence rate of outcomes within 30 days of LT was 12.8% (range, 1.1-23.2%). 17, 21, 22, 24, 28, 32, 33 The average outcome incidence rate for events 6 months or shorter post-LT was 22.6% (range, 1.1%-50%). 2, 17, [21] [22] [23] [24] 28, [31] [32] [33] 38 For events longer than 6 months post-LT, incidence rate was 11.8% (range, 0-31.4%). 9, [13] [14] [15] [16] 18, 19, 21, 22, 25, 26, 32, [34] [35] [36] Predictors of CV Events A detailed list of the predictors evaluated and the results of univariate analysis is provided in Table S3 , SDC (http://links. lww.com/TP/B419). For each study, the predictor variables were categorized as follows: (1) clinical characteristics, including demographics and relevant comorbidities; (2) intra/ postoperative factors including donor characteristics; or (3) pre-LT cardiac testing. Multivariable analysis was performed in all 23 studies. The results of these analyses are detailed in Table 3 . Among the variables assessed, older age (most often analyzed as a continuous variable per year) was the most consistent independent predictor of clinical outcomes (significant on multivariate analysis in 8 of 23 studies; effect size range per year increase 1.02-1.17 and 2.2 per decade increase). This was followed by history of cardiac disease, MELD score, and pre-LT transthoracic echocardiography (TTE) data (each significant in 7, 5, and 5 studies, respectively) ( Figure 2 ). For patients with a history of cardiac disease, the effect size ranged from 1.8 to 7.7. Of note, indication for liver transplant, BMI, and diabetes were not identified as being consistent independent predictors of CV outcomes post-LT (significant in multivariable analysis in 4, 4, and 1 studies, respectively). The reported performance characteristics of differing cardiac imaging modalities to risk stratify patients for CV outcomes post-LT are shown in Table S4 , SDC, http://links. lww.com/TP/B419. 8, 9, 28, 30, 37 The sensitivity, specificity, NPV, and PPV of DSE in LT candidates across these studies were discordant. 8, 9, 28, 30 Sensitivity of DSE for CV events post-LT ranged from 0% to 80% with PPV of 11% to 40%. The reported specificity and NPVof DSE for CVevents post-LT was also strikingly variable with ranges of 47% to 100% and 48% to 93%, respectively. Studies analyzing SPECT testing reported high NPV (91%-99%).
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Prediction Models
Five studies provided prediction models, though none had been externally validated ( Table S5 , SDC, http://links.lww. com/TP/B419). 19, 21, 22, [31] [32] [33] Overall, the majority of the components of the prediction models included a combination of demographic information, laboratory data, prior cardiac disease history, and cardiac testing results. The area under the receiver operating characteristic curve for these models were modest (range 0.66-0.75) with the exception of the models by Guckelberger et al 19 that reported an area under the receiver operating characteristic curve of 0.78 and 0.80.
Quality Assessment and Risk of Bias
Studies evaluating predictors of CVoutcomes post-LT were in general assessed as being high quality (Table S2 , SDC, http://links.lww.com/TP/B419). Five studies had patient cohorts with limited representativeness compared with the overall patient population of interest and 1 study only provided limited data regarding the patient cohort. 14, 19, 24, [33] [34] [35] Among the cardiac imaging studies, 2 studies were assessed as having limited representativeness given the inclusion and exclusion criteria.
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DISCUSSION
In the setting of the aging baby boomer population, the increasing indication of NAFLD for LT, and the uptick in number of patients needing dual liver-kidney transplants, the incidence of CV events post-LT is likely to increase. Although CVevents represent a major source of morbidity and mortality post-LT, our review highlights the critical gaps in knowledge on this topic including quantifying the true scope of the problem, identifying patients at highest risk for these outcomes, and defining the optimal risk stratification approach to try and minimize the frequency of these adverse events. Herein, we highlight the inconsistency in outcome definitions and detail the stark variability in ranges of reported outcome incidence stemming from these variations (1-41% for outcomes ≤ 6 months and 0-31% for outcomes > 6 months post-LT). In addition, we identified the variables that despite study heterogeneity were consistently associated with a higher risk of CV events post-LT, namely, older age and a prior history of cardiac disease. Moreover, we demonstrate the conflicting data regarding the performance characteristics of various cardiac imaging techniques including those commonly used in clinical practice.
In this context, our review details several areas in need of attention from the liver transplant community. First, there is a clear need to identify a consensus definition for clinically relevant CV events post-LT. Until such time that the specific outcomes of interest are selected and then subsequently uniformly and prospectively assessed for, the transplant community will be unable to accurately quantify the burden of CV outcomes post-LT. Based on the existing data and on current clinical practice, endpoints to be considered in the consensus definition likely include acute coronary syndrome (ST elevation MI, non-ST elevation MI, and unstable angina), clinically significant arrhythmias (ventricular tachycardia and fibrillation, atrial fibrillation and flutter, and symptomatic heart block), heart failure, stroke, and cardiac arrest or primary cardiac death stemming from 1 of these processes. Future studies should consider grading of CVevents after transplantation, using the Clavien-Dindo classification, to allow identification of events associated with significant morbidity and mortality, as opposed to transient events without sequelae. 39 Only with prospective surveillance for these specific outcomes and their severity, instead of the retrospective analyses with variable endpoints, can the true incidence and optimal risk assessment for CV events be ascertained.
A second focus area for the transplant community relates to the need to more accurately identify patients who require intensive cardiac risk stratification. Results of the multivariate analyses in the included studies demonstrated that incremental increase in age (effect size, 1.02-1.17 per year) and background cardiac disease (effect size, 1.8-7.7) were consistently associated with higher risk of CV events post-LT. Though these findings are unsurprising and relatively nonspecific, our study is the first to systematically assess and compare the specific risk factors from among the many potential contributing variables that portend worse prognosis in terms of risk of a CVevent post-LT. These 2 specific risk factors are highly relevant from a clinical practice standpoint as the overall liver transplant candidate pool continues to age and present with increasing numbers of comorbid conditions. Similarly, notable is the lack of data to support the role of other variables that are often thought to convey increased risk for cardiac outcomes. For example, diabetes, obesity and NAFLD did not appear to consistently be associated with higher risk of CV events post-LT. The reasons for this lack of independent association for these variables that have biologic plausibility for driving CV risk is unclear, but is likely in part due to differences in study design and characteristics of patients enrolled in these studies (likely driven by substantial center-level variability in recipient selection and relative tolerance of specific comorbidities).
A third key area of focus is the need to better characterize the specific performance characteristics of the various cardiac testing modalities in this patient population. Our data emphasize the conflicting predictive accuracy of the most commonly employed cardiac imaging testing, DSE. Presently, there are multiple alternative cardiac imaging modalities, but existing data are unable to direct clinicians to the optimal testing tool. The studies querying imaging modalities were often quite small, and specific methodology and expertise may vary across centers, limiting the generalizability of these findings to real world clinical practice.
Until such time that the above limitations can be addressed prospectively in future studies, our data would support a tailored cardiac risk stratification approach based on these risk Includes Standard TTE data and data from DSE.
factors. Although we were not able to concretely identify a threshold age at which CV events drastically increase, given that enrolled patients consisted primarily of middle-aged adults, the additional accrued risk above age 60 years, which appears to confer a relative risk of at least 1.5 times higher than younger patients, is likely to be of clinical significance. This age parameter along with cardiac disease history could potentially represent prompts for more detailed CV testing. Given potential limitations of DSE, our center has recently implemented a new tailored risk-based protocol that incorporates our findings. LT candidates with 2 or more of the following risk factors now undergo additional cardiac imaging testing after DSE: age 60 years or older, BMI higher than 35, diabetes, arrhythmia requiring treatment, or prior history of coronary artery revascularization or stroke. We have selected positron emission tomography/computed tomography, a nuclear medicine imaging modality that is gaining favor due to its ability to calculate myocardial blood flow and flow reserves that have been shown to be independently prognostic of cardiac events, as our additional imaging modality. 40, 41 The performance characteristics of positron emission tomography/computed tomography in LT candidates needs to be studied in further detail however.
In conclusion, this study is the first systematic review and analysis of the large body of literature on the topic of CV events after liver transplantation. Through this review, we have outlined the patient characteristics of older age and previous history of cardiac disease as being consistently associated with increased risk for adverse cardiac outcomes post-LT. We have also highlighted the areas in which the transplant community can make significant strides to mitigate these outcomes in the post-LT setting, including refining the evaluation of patients at highest risk for adverse cardiac outcomes and ongoing assessment of the optimal cardiac imaging modalities. From a health policy standpoint, if specific patient risk profiles, and refined screening methods, were able to be more definitively characterized, a more directed approach to cardiac risk stratification could be implemented and in turn could help balance the risks, benefits and cost effectiveness of different testing processes with the ultimate goal of reducing the rates of CV events in the posttransplant setting.
